You are here

Approvals, Launches, and New Indications

Agent can also be used perioperatively in some patients to reduce the need for transfusions
Drug indicated for use prior to surgery to boost platelet counts
Novel drug is a first-in-class treatment that reduces migraine occurrence
Lucemyra indicated for up to 14 days as part of a long-term treatment plan
First drug approved to treat MS in patients as young as 10 years old
Drug used in combination with bortezomib, melphalan, and prednisone
Kymriah now indicated for relapsed or refractory diffuse large B cell lymphoma
This is the third indication granted for the co-administered drugs
Approval based on clinical studies and real-world evidence
Lowest, total-volume preparation bowel cleanser available in U.S.
Placenta-based stem cell therapy treats bone marrow unable to produce enough blood cells
Treatment benefits certain patients with BRAF V600-mutant disease
Agent indicated for patients at risk for autosomal dominant polycystic kidney disease
Drug normalized phosphorus levels and improved x-ray findings in trials
Drug indicated for adults unresponsive to previous therapies
Drug improved progression-free survival in trial versus Tarceva or Iressa
Pathogen can cause serious treatment-resistant infections in hospitalized patients
Regimen showed significant improvement in overall survival in trial versus Sutent
Drug is first and only approved specific reversal agent for a novel oral anticoagulant
Test performed in the primary care setting may improve access to screening

Pages